Article

Autoantibodies to the adenosine triphosphate synthase play a pathogenetic role in Alzheimer's disease

Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Rome, Italy.
Neurobiology of aging (Impact Factor: 4.85). 04/2012; 33(4):753-66. DOI: 10.1016/j.neurobiolaging.2010.05.013
Source: PubMed

ABSTRACT It has become evident that an autoimmune component could play a role in Alzheimer's disease (AD) onset and/or progression. The aim of this study was to identify neuronal antigenic targets specifically recognized by serum autoantibodies and to investigate their cellular effects and their possible pathogenetic role. We identified, by an immunoproteomic approach using mouse brain proteins, the adenosine triphosphate (ATP) synthase β subunit as a new autoantigen in AD. Using an ELISA assay we found that serum anti-ATP synthase autoantibodies were present in 38% of patients with AD, but in no age-matched healthy subjects or in patients with Parkinson's disease or atherosclerosis. Analytical cytology studies, using SH-SY5Y neuroblastoma cell line, showed that ATP synthase autoantibodies were capable of inducing the inhibition of ATP synthesis, alterations of mitochondrial homeostasis and cell death by apoptosis. These findings suggest that autoantibodies specific to ATP synthase can exert a pathogenetic role via a mechanism that brings into play the impairment of the extracellular ATP homeostasis and the alteration of mitochondrial function triggering cell death by apoptosis.

Download full-text

Full-text

Available from: Maurizio Sorice, Nov 17, 2014
1 Follower
 · 
174 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the past few years, several reports have described the presence of F0F1 ATP synthase subunits at the surface of hepatocytes, where the hydrolytic activity of F1 sector faces outside and triggers HDL endocytosis. An intriguing question is whether the ectopic enzyme has same subunit composition and molecular mass as that of the mitochondrial ATP synthase. Also due to the polar nature of hepatocytes, the enzyme may be localized to a particular cell boundary. Using different methods to prepare rat liver plasma membranes, which have been subjected to digitonin extraction, hr CN PAGE, immunoblotting, and mass spectrometry analysis, we demonstrate the presence of ecto-F0F1 complexes which have a similar molecular weight to the monomeric form of the mitochondrial complexes, containing both nuclear and mitochondrially-encoded subunits. This finding makes it unlikely that the enzyme assembles on the plasma membranes, but suggest it to be transported whole after being assembled in mitochondria by still unknown pathways. Moreover, the plasma membrane preparation enriched in basolateral proteins contains much higher amounts of complete and active F0F1 complexes, consistent with their specific function to modulate the HDL uptake on hepatocyte surface.
    Journal of Bioenergetics 08/2013; DOI:10.1007/s10863-013-9522-z · 2.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lipid peroxidation involves a cascade of reactions in which production of free radicals occurs selectively in the lipid components of cellular membranes. Polyunsaturated fatty acids easily undergo lipid peroxidation chain reactions, which, in turn, lead to the formation of highly reactive electrophilic aldehydes. Among these, the most abundant aldehydes are 4-hydroxy-2-nonenal (HNE) and malondialdehyde, while acrolein is the most reactive. Proteins are susceptible to posttranslational modifications caused by aldehydes binding covalently to specific amino acid residues, in a process called Michael adduction, and these types of protein adducts, if not efficiently removed, may be, and generally are, dangerous for cellular homeostasis. In the present review, we focused the discussion on the selective proteins that are identified, by redox proteomics, as selective targets of HNE modification during the progression and pathogenesis of Alzheimer disease (AD). By comparing results obtained at different stages of the AD, it may be possible to identify key biochemical pathways involved and ideally identify therapeutic targets to prevent, delay, or treat AD.
    Free Radical Biology and Medicine 10/2012; 62. DOI:10.1016/j.freeradbiomed.2012.09.027 · 5.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Growing evidence suggests that autoantibodies specific to distinct molecular antigens are present in sera or cerebrospinal fluids from patients with Alzheimer's disease (AD). They could have a protective (i.e., anti-β-amyloid) or a pathogenetic role (i.e., anti-GM1 or anti-ATP synthase) but, in any case, they might be considered as useful diagnostic or prognostic markers of the disease. In this review, we briefly summarize the autoantibodies known to be detectable in patients with AD and we discuss their potential role in the pathogenesis of the disease, as well as their potential use as peripheral blood biomarkers.
    Autoimmunity reviews 10/2010; 9(12):807-11. DOI:10.1016/j.autrev.2010.07.008 · 7.10 Impact Factor